Teva Appoints Michael Hayden As President Of Global Research And Development And Chief Scientific Officer

Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) today announced that Dr. Michael R. Hayden, will join the company as the President of Global Research and Development and Chief Scientific Officer, based in Israel. In this new role, Dr. Hayden will lead all research and development for Teva, thus combining the efforts of two world-class teams focused on the development of both brand and generic medicines.

Dr. Hayden is currently Killam Professor of Medical Genetics at the University of British Columbia, and Canada Research Chair in Human Genetics and Molecular Medicine. He is also the founder and Director/Senior Scientist of the Centre for Molecular Medicine and Therapeutics at the University of British Columbia. He is a preeminent expert in genetics and personalized medicine and is one of the world’s leading experts on Huntington’s disease. Dr. Hayden has extensive experience in all aspects of drug development – from target identification, to all stages of clinical development through to drug submission to the various regulatory agencies around the world.

Dr. Jeremy Levin, Teva’s incoming President and Chief Executive Officer stated, “We are delighted to have Michael join us as our Chief Scientific Officer. He brings to Teva world-renowned experience and knowledge in scientific and clinical research coupled with deep knowledge of discovery and development of medicines. His deeply innovative approach and very strong leadership capabilities make him a true asset for Teva, our customers and the patients we serve.”

Commenting on his appointment, Dr. Hayden said: “I am thrilled to be leading Teva’s world-renowned R&D organization and to be working under Dr. Jeremy Levin's leadership. We have a tremendous opportunity to redefine the way we traditionally develop medicines by focusing on research and development as a whole, and not by how the product will be commercialized.”

Dr. Hayden has founded three biotechnology companies: NeuroVir; Aspreva Pharmaceuticals; and Xenon Genetics Inc. He has received numerous prestigious awards, including the Killam Prize and the Canada Gairdner Wightman award in 2011; the Order of Canada in 2010; Order of British Columbia in 2009; Canada's Health Researcher of the Year in 2008 and the Distinguished Scientist Award of the Canadian Society of Clinical Investigation in 1998.

1 2 3 Next › Last »